Efficacy and Safety of Ciprofloxacin Extended-Release [BAYQ3939, Cipro XR] 1000 mg Once-Daily Versus Ciprofloxacin Immediate-Release [BAYQ3939, Cipro IR] 500 mg Twice-Daily Given 7-14 Days in Patients With Complicated Urinary Tract Infections: Prospective, Randomized, Double-Blind Trial.

Trial Profile

Efficacy and Safety of Ciprofloxacin Extended-Release [BAYQ3939, Cipro XR] 1000 mg Once-Daily Versus Ciprofloxacin Immediate-Release [BAYQ3939, Cipro IR] 500 mg Twice-Daily Given 7-14 Days in Patients With Complicated Urinary Tract Infections: Prospective, Randomized, Double-Blind Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2011

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Bacterial infections; Urinary tract infections
  • Focus Therapeutic Use
  • Acronyms EMERON
  • Sponsors Bayer
  • Most Recent Events

    • 22 Mar 2011 Results presented at the 26th Congress of the European Association of Urology.
    • 01 Dec 2009 Results published in the Journal of Chemotherapy.
    • 01 Dec 2009 Planned number of patients changed from 212 to 304 according to results published in the Journal of Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top